RxAmerica partners with SureScripts to provide e-prescribing capabilities
SALT LAKE CITY Pharmacy benefit management company RxAmerica will provide electronic prescribing to prescribers and plans with SureScripts, RxAmerica announced Monday.
Alexandria, Va.-based SureScripts operates an electronic communications network that connects physicians to pharmacies through e-prescribing, which eliminates paper from the prescription process and, according to the Center for Information Technology Leadership, could prevent 130,000 life-threatening medication errors a year in addition to saving time. Its network includes drug store chains such as Duane Reade, CVS, Longs Drugs and Walgreens.
“We are very excited to be working with SureScripts to provide the value of safety and efficiency to our customers and their members,” said John Gardynik, president of RxAmerica. “It has been shown that e-prescribing increases both the efficiency of plan practices and the accuracy of the prescribing process.”
RxAmerica is a subsidiary of Longs Drug Stores.
ShopKo to open in-store clinics in Wisconsin
MADISON, Wis. Meriter, a provider of healthcare services, has teamed up with ShopKo to open two FastCare clinics in Madison in mid-October.
Meriter’s clinics, which will be located in ShopKo East and ShopKo West, will be staffed by nurse practitioners who can offer treatment for such acute ailments as pink eye, bladder infections and skin rashes. The n.p. can write a prescription, if needed.
“We’re very pleased to provide this service to residents, as well as visitors, to our community,” stated Geoff Priest, Meriter chief medical officer. “Providing quality health care that is convenient, both in hours and location, is very important to us at Meriter.”
Green Bay, Wis.-based Bellin Hospital, in partnership with ShopKo, started the FastCare concept. Since then, they have negotiated partnerships with other health care systems, including ThedaCare in Appleton, Aspirus in Wausau and Olmstead in Rochester, Minn. Others underway include Beaver Dam and one in Waukesha.
Alnylam inks potential $93 million deal with Kyowa Hakko Kogyo
CAMBRIDGE, Mass. Alnylam Pharmaceuticals has signed a collaborative deal with Kyowa Hakko Kogyo, that could be worth as much as $93 million, to develop and market the experimental respiratory drug ALN-RSV01, according to the Associated Press.
ALN-RSV01 is currently in midstage development for respiratory syncytial virus, which can cause severe lower respiratory infections, particularly in infants. Most of Alynlam’s pipeline, though, is still in the preclinical phase of development, with potential candidates for liver cancer, Huntington’s disease, pandemic flu, and cystic fibrosis, among others.
This is the company’s second recent deal. At the end of May, Alnylam signed a research partnership deal with Takeda Pharmaceuticals worth as much as $1 billion.